UK's OptiBiotix Health H1 revenue jumps on Asia, Europe growth
UK's OptiBiotix Health H1 revenue jumps on Asia, Europe growth
Overview
UK life sciences firm's H1 revenue rose 22% yr/yr, driven by growth in Asia and Europe
Gross profit climbed 25%, with margin improving to 55.9% from 54.4%
Company reduced selling and R&D costs, narrowing operating loss from prior year
Outlook
Company expects further cost reductions in H2 2026 from lower manufacturing and absence of one-off costs
OptiBiotix prioritises commercialisation of SweetBiotix, targeting initial product samples around end-2026
Company sees growing commercial interest in SweetBiotix and an expanding international customer pipeline
Result Drivers
ASIAN SALES GROWTH - Strong sales in Asia and 'Rest of World' markets, particularly a 133% increase in Asia, offset weaker performance in the US and India
COST REDUCTIONS - Lower selling, R&D and patent costs, including a 69.5% drop in selling costs, supported margin improvement and reduced operating loss
AI-DRIVEN MARKETING - Introduction of AI tools for Amazon marketing increased return on spend to 3.6X from 1.2X, improving marketing efficiency and boosting organic sales
Company press release: ID:nRSQ0844Va
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| GBP 679,000 |
|
H1 EBIT |
| -GBP 753,000 |
|
H1 Gross Profit |
| GBP 380,000 |
|
Reuters Recommended Reads
Sept 15 - UK's ValiRx half-year loss narrows, cash position improves
Sept 15 - UK's ImmuPharma interim net loss widens on derivative finance loss
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)